

**Technology Advisory Committee A Interests Register**

**Trastuzumab deruxtecan for treating HER2-Low metastatic or unresectable breast cancer after chemotherapy ID3935**

**Publication Date: 27 March 2024**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Andrew Clamp	Expert	Financial Interests	<p>Advisory board and speaker's fees from GSK related to dostarlimab in endometrial cancer.</p> <p>Advisory board fees from Immunogen and Clovis oncology regarding ovarian cancer treatments.</p>	05/12/2023	It was agreed that Andrew's declaration would not prevent him from providing expert participation this appraisal.
Laura Tookman	Expert	Financial Interests	<p>Since 2018: Served on advisory boards for astrazeneca and Clovis Oncology, received consulting fees from Tesaro, astrazeneca, GSK and Clovis oncology, Received honoraria for lectures and presentations from Clovis Oncology, GSK, Astrazeneca and MSD. Sponsorship for travel and conference attendance from Tesaro and Astrazeneca.</p>	05/12/2023	It was agreed that Laura's declaration would not prevent her from providing expert participation this appraisal.
Laura Tookman	Expert	Non-financial Interests	<p>PI/Sub I on trials for drugs for endometrial cancer. Steering committee member for trial sponsored by GSK (ongoing)</p>	05/12/2023	It was agreed that Laura's declaration would not prevent her from providing expert participation this appraisal.

Laura Tookman	Expert	Indirect Interests	<p>Current research projects:            Developing mechanisms for analysing real world data to improve outcomes in gynaecological malignancies (funded by Imperial Health Charity) in collaboration with the iCARE (Imperial clinical Analytics, Research and Evaluation) team.            CI for BritROC 2: Translational Research sample collection study for ovarian cancer</p>	05/12/2023	<p>It was agreed that Laura's declaration would not prevent her from providing expert participation this appraisal.</p>
---------------	--------	--------------------	---	------------	---

<p>Helen White</p>	<p>Patient Expert</p>	<p>Financial Interests</p>	<p>Helen received £120 from GSK in July 2022 for participating in a live virtual expert patient discussion at an Oncology Business meeting.</p> <p>Additionally, the following is noted for the nominating organisation:</p> <p>Peaches Womb Cancer Trust has received several payments from GlaxoSmithKline (GSK) over the past few years. These grants are unrelated to a product mentioned in the stakeholder list except for review of the 'Jemperli' booklet (point 3. below):</p> <p>1. £2512 payment received in Oct 2023 for employee and trustee time spent on an awareness campaign that involved collaboration with GSK and another gynae charity.</p> <p>1.</p> <p>2. £9,960 grant received in Jan 2023 to create a series of bite-sized videos that will be hosted on Peaches website to provide support to people affected by womb cancer.</p>		<p>It was agreed that Helen's declaration would not prevent her from providing expert participation this appraisal.</p>
--------------------	-----------------------	----------------------------	--	--	---

			<p>3. £240 payment received in May 2022 for review of 'Jemperli' (dostarlimab) booklet.</p> <p>4. £180 payment received in Dec 2021 for a presentation on womb cancer delivered to GSK employees.</p> <p>5. £8000 grant received in 2021 to fund merchandise and distribution costs of Clinical Nurse Specialist information packs for patients.</p> <p>Peaches Womb Cancer Trust also received a £100 honorarium from Eisai in Oct 2022 for a trustee's attendance at an endometrial cancer advisory meeting.</p>		
Becky Pennington	Committee Member	Direct – Financial Interests	On 1 Dec Becky spoke at a symposium about Spillovers in Economic Evaluation. Her travel & accommodation was paid for by GlaxoSmithKline. There is no payment for the work. The symposium is about methodological research and her presentation is not related to this drug or indication.	15/11/2023	It was agreed that Becky's declaration would not prevent her participating in discussions on this appraisal.
Patrick de Barr	Committee Member	Direct – Financial Interests	Patrick's company are now investigating PD1 in gynae	15/11/2023	It was agreed that Patrick's declaration would prevent

			<p>cancers including endometrial cancers</p> <p>Patrick received paid employment from a company (Incyte) who are developing a monoclonal antibody against PD1. This is in a different lead indication to the appraisal</p>	24/10/2023	<p>him from participating in discussions on this appraisal.</p> <p>It was agreed that Patrick's declaration would not prevent him from participating in discussions on this appraisal.</p>
James Fotheringham	Committee Member	Financial Interests	James performed a literature review on remote monitoring in dialysis for Baxter Healthcare, fees paid to his institution.	05/09/2023 17/10/2023	It was agreed that James' declaration would not prevent him from participating in discussions on this appraisal.
Peter Schmid	Clinical Expert	Direct financial interests	Consultancy and honorarium from AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Pfizer, Puma, Roche	05/09/2023 07/11/2023	It was agreed that Peter's declaration would not prevent him from participating in discussions on this appraisal.
Peter Schmid	Clinical Expert	Indirect interests	Grant/Funding to Institution from: Astellas, AstraZeneca, Genentech, Novartis, Oncogenex, Roche, Medivation	05/09/2023 07/11/2023	It was agreed that Peter's declaration would not prevent him from participating in discussions on this appraisal.

Kirstin Spencer	Patient expert	Indirect financial	Kirstin's nominating organisation were awarded an unconditional grant of from Daiichi Sankyo to contribute to the running of a Metastatic Breast Cancer Conference in Manchester on 13 June 2023. The objective of the conference was to highlight a case for change that can be shared by Cancer Alliances and health systems across England and the rest of the UK. Daiichi Sankyo had no input into the agenda, selection of speakers, scientific content or arrangement.	02/08/2023  07/11/2023	It was agreed that Kirstin's declaration would not prevent her from participating in discussions on this appraisal.
Hugo Pedder	Committee Member	Direct financial	Hugo expects to receive financial payment from Baxter Healthcare within the next 6 months for work on a treatment and indication unrelated to this.	20/10/2023	It was agreed that Hugo's declaration would not prevent him from participating in discussions on this appraisal.

